格隆汇3月31日丨山东新华制药股份(00719.HK)宣布，公司非执行董事徐列因达退休年龄辞任公司董事 以及董事会发展战略委员会成员职务。该辞任自2026年3月31日起生效，之后徐列在公司已无担任任何 职位及职务。 ...

山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） | 賀同慶先生（董事長） | 潘廣成先生 | | --- | --- | | 徐文輝先生 | 朱建偉先生 | | 侯 寧先生 | 凌沛學先生 | | | 張菁菁女士 | （股份編號：00719） 董事名單與其角色和職能 山東新華制藥股份有限公司董事會（「董事會」）成員載列如下： | | | 執行董事 : 獨立非執行董事 : 非執行董事 : 張成勇先生 董事會設立 4 個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | 董事/委員會 | 提名委員會 | 薪酬與考核委員會 | 審核委員會 | 戰略發展委員會 | | --- | --- | --- | --- | --- | | 賀同慶先生 | M | | | C | | 徐文輝先生 | M | | | M | | 張成勇先生 | | | | M | | 侯 寧先生 | | | | M | | 潘廣成先生 | C | M | M | M | | 朱建偉先生 | M | C | M | M | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （于中華人民共和國註冊成立之股份有限公司） （股份代碼：0719） 非執行董事辭任 山東新華製藥股份有限公司（「本公司）董事會（「董事會」）謹此宣佈，本公司非執行董事 徐列先生（「徐先生」）因達退休年齡辭任（「該辭任」）本公司董事以及董事會發展戰略委員 會成員職務。該辭任自 2026 年 3 月 31 日起生效，之后徐先生在本公司已無擔任任何職位及 職務。 徐先生確認並無與董事會持不同意見，亦不知悉就該辭任有任何事宜須提呈本公司股東及 香港聯合交易所有限公司垂注。 本公司謹藉此機會，衷心感謝徐先生於任職期間內所作寶貴貢獻。 承董事會命 山東新華製藥股份有限公司 賀同慶 董事長 中國 淄博 2026年3月31日 於本公告日期，本公司董事會之成員如下： 執行董事： 獨立非執行董事： 賀同慶先 ...

Core Viewpoint - Xinhua Pharmaceutical is experiencing a situation of "increased revenue but decreased profit" for the second consecutive year, with significant declines in overseas revenue and a record low revenue growth rate over the past decade [1][3][4]. Financial Performance - In 2025, Xinhua Pharmaceutical achieved an operating revenue of 8.755 billion yuan, a year-on-year increase of 3.41%, while the net profit attributable to shareholders was 290 million yuan, down 38.32% year-on-year [2][3]. - The company's net profit excluding non-recurring items was 268 million yuan, a decrease of 40.10% year-on-year [1][2]. - The revenue growth rate of 3.41% in 2025 is the lowest in nearly 10 years, marking a trend of "increased revenue but decreased profit" for two consecutive years [3][4]. Revenue Breakdown - Domestic revenue in China reached 6.785 billion yuan, up 7.15% year-on-year, while revenue from the Americas fell by 19.09% to 746 million yuan, and revenue from Europe decreased by 10.72% to 713 million yuan [4]. Cost Management - Research and development expenses for 2024 and 2025 were 413 million yuan and 382 million yuan, respectively, showing a decline of 1.44% and 7.64% year-on-year [1][7]. - Sales expenses also decreased significantly, with 2025 sales expenses at 341 million yuan, down 41.67% year-on-year [5][9]. Product Development - In 2025, Xinhua Pharmaceutical obtained 47 drug approvals, a historical high, and launched 28 new formulations, with 27 more products accelerating towards market entry [6][8]. - The international formulation business saw a revenue increase of 19.86%, with self-operated formulation exports rising by 176.13% [6]. Strategic Outlook - The company remains optimistic about future growth opportunities, citing national strategic support for the pharmaceutical industry and the potential for domestic formulation exports [9].

Group 1 - The company, XinHua Pharmaceutical, is focusing on research and development across multiple therapeutic areas including cardiovascular, analgesic, digestive, metabolic, and neurological systems [1] - The R&D efforts include both innovative drugs and generic drugs [1]

Group 1 - The core viewpoint of the article is that Xinhua Pharmaceutical reported its 2025 annual results, showing a revenue increase but a significant decline in net profit [1] Group 2 - The company achieved an operating revenue of 8,754,721,987.78 yuan for the year 2025, representing a year-on-year growth of 3.41% [1] - The net profit attributable to shareholders of the listed company was 289,888,855.00 yuan, reflecting a year-on-year decrease of 38.32% [1]

Core Viewpoint - Xinhua Pharmaceutical announced the approval of multiple proposals during the 10th meeting of the 11th Board of Directors, including the 2025 annual report and performance announcement, profit distribution for 2025, and the reappointment of the accounting firm [1] Group 1 - The company approved the proposal for the 2025 annual report and performance announcement [1] - The proposal regarding the profit distribution for the year 2025 was also approved [1] - The reappointment of the accounting firm was included in the approved proposals [1]

Core Viewpoint - The announcement by Xinhua Pharmaceutical regarding the approval of the 2026 remuneration plan for directors and senior management emphasizes a performance-based compensation structure, with a significant portion tied to company performance and individual achievements [1] Group 1: Compensation Structure - The remuneration plan for non-independent directors includes a basic salary, performance pay, and long-term incentives, with performance pay accounting for no less than 60% of total compensation [1] - Independent directors' allowances will be subject to approval by the shareholders' meeting [1] - Senior management compensation is similarly structured, with a minimum of 60% of total pay linked to performance, and basic salaries paid monthly, while other components are settled post-annual audit [1]

Group 1 - The core point of the article is that Xinhua Pharmaceutical announced a change in accounting policy, which will take effect from January 1, 2026, in accordance with the Ministry of Finance's "Interpretation No. 19 of the Accounting Standards for Enterprises" [1] - The changes involve five aspects, including the recognition of compensatory assets in business combinations under common control and the termination of recognition of financial liabilities related to electronic payment system settlements [1] - The board's decision does not require submission to the shareholders' meeting and will not affect the company's financial position, operating results, or cash flows [1]

Core Viewpoint - Xinhua Pharmaceutical announced the proposal to reappoint Crowe Horwath as the auditing firm for the fiscal year 2026, with an audit service fee of 760,000 yuan (including tax) [1] Group 1 - The audit service fee is set at 760,000 yuan, which includes tax [1] - The proposal has been approved by the board of directors and is pending approval from the shareholders' meeting [1] - The signing project partner is Li Chunxu, with independent review partner Liu Zhizeng and signing CPA Kong Xiangnan [1]